AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1350803
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 10 mg/ml
Trial: 1350803
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 30 mg/ml
Trial: 6209080
Drug: Lorcainide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcainide (100 mg/d by mouth, three times daily)
Trial: 22398060
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily mesalazine (1×2 g)
Trial: 22398060
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily mesalazine (2×1 g)
Trial: 15740828
Drug: Intravenous pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentazocine (0.5mg/kg)
Trial: 12164994
Drug: Preventive occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive occupational therapy (OT)
Trial: 10207539
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg three times a day
Trial: 10207539
Drug: Ritonavir 600
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 600 mg twice a day
Trial: 10207539
Drug: Ritonavir 400
RxNorm normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 400 mg twice a day and saquinavir 400 mg twice a day
Trial: 10207539
Drug: Indinavir (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (in antiretroviral drug-naive patients)
Trial: 10207539
Drug: Ritonavir (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (in antiretroviral drug-naive patients)
Trial: 10207539
Drug: Ritonavir +
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir + saquinavir (in antiretroviral drug-naive patients)
Trial: 10207539
Drug: Indinavir (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (in drug-experienced patients)
Trial: 10207539
Drug: Ritonavir (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (in drug-experienced patients)
Trial: 10207539
Drug: Ritonavir +
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir + saquinavir (in drug-experienced patients)
Trial: 9097805
Drug: Subconjunctival mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival mitomycin C (0.5 mg/ml) applied for 1-, 3-, or 5-minutes
Trial: 2710266
Drug: Intravenous ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ranitidine 50 mg
Trial: 2710266
Drug: Oral ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ranitidine 150 mg
Trial: 47944
Drug: C.F. antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.F. antibodies (IgG)
Trial: 31941483
Drug: Intraarticular HADMSCs
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular HADMSCs injection with LIPUS
Trial: 31941483
Drug: Intraarticular HADMSCs
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular HADMSCs injection with sham LIPUS
Trial: 23881774
Drug: Soy fiber
RxNorm normalized name: Soy Fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy fiber (SF) biscuits (approximately 100 g/day) for 12 weeks
Trial: 21441616
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg daily) for 30 and 90 days
Trial: 19624576
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg, maximum 400 mg)
Trial: 19624576
Drug: Acetaminophen-codeine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen-codeine (1 mg/kg as codeine, maximum 60 mg)
Trial: 17105953
Drug: GHB 40
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 40 mg/kg
Trial: 17105953
Drug: GHB 50
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 50 mg/kg
Trial: 17105953
Drug: GHB 60
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 60 mg/kg
Trial: 17105953
Drug: GHB 72
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 72 mg/kg
Trial: 15152747
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K antagonists (e.g., warfarin) for stroke prevention in AF
Trial: 12100790
Drug: Computer Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer Assisted Meal Related Insulin Therapy (CAMIT)
Trial: 12100790
Drug: Multiple Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Subcutaneous Injection (MSI)
Trial: 9166489
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of paclitaxel (135 mg/m2)
Trial: 9166489
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of paclitaxel (200 mg/m2)
Trial: 9166489
Drug: 3-day divided
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day divided dose schedule of paclitaxel (200 mg/m2)
Trial: 9166489
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of paclitaxel (135 mg/m2 and 200 mg/m2)
Trial: 9166489
Drug: 200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 dose of paclitaxel in non-small cell lung cancer
Trial: 334211
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once-daily
Trial: 334211
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg once-daily
Trial: 334211
Drug: Atenolol 200
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 200 mg once-daily
Trial: 31216226
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6)
Trial: 31216226
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22)
Trial: 31216226
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus concurrent and maintenance bevacizumab (stage IV)
Trial: 31216226
Drug: Chemotherapy control
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy control (n = 625)
Trial: 27895192
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (including Ca++-channel blockers and diuretics)
Trial: 25880685
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus CMC 1% (n = 90)
Trial: 25880685
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (control group, n = 90)
Trial: 17416480
Drug: Initial serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial serum creatinine > 150 μmol/L
Trial: 17416480
Drug: Initial serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial serum creatinine ≤ 150 μmol/L
Trial: 17416480
Drug: Initial route
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial route of CYC administration
Trial: 15543358
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with 0.625 mg of equine conjugated estrogens and 2.5 mg of medroxyprogesterone
Trial: 9590593
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% eyedrops (10 times)
Trial: 9590593
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% eyedrops (6 times)
Trial: 9590593
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin (200 mg)
Trial: 9590593
Drug: Intravenous ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ofloxacin (200 mg)
Trial: 28216244
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (5 doses of 2.7 x 10^5 PfSPZ at days 0, 28, 56, 84, and 140)
Trial: 25894892
Drug: β-Alanine (BA)
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-Alanine (BA) supplementation (4.0-5.6 g day(-1))
Trial: 17087307
Drug: Cell transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell transplantation therapy
Trial: 14627786
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg once weekly)
Trial: 28573743
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg twice weekly)
Trial: 10831972
Drug: Danazol 200
RxNorm normalized name: danazol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 200 mg three times daily for 6 months
Trial: 10831972
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 3.75 mg depot every 28 days for 6 months
Trial: 9356085
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 15 mg/kg before CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Trial: 9356085
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 15 mg/kg after CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Trial: 9356085
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 15 mg/kg before CPB
Trial: 9356085
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 15 mg/kg after CPB
Trial: 8210561
Drug: Initial steroid
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial steroid pulses 500 mg x3 (n = 17)
Trial: 8210561
Drug: Low oral
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low oral steroid treatment (n = 20)
Trial: 8210561
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (n = 3)
Trial: 3820944
Drug: Intravenous deferoxamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous deferoxamine, 40 mg/kg
Trial: 3820944
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and intraperitoneal deferoxamine
Trial: 24746177
Drug: Aprepitant add-on
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant add-on triple antiemetic therapy (with a 5-HT(3) receptor antagonist and dexamethasone)
Trial: 24746177
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic therapy (5-HT(3) receptor antagonist and dexamethasone)
Trial: 24746177
Drug: Aprepitant add-on
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant add-on therapy in patients taking carboplatin and pemetrexed
Trial: 24746177
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic therapy in patients taking carboplatin and pemetrexed
Trial: 23236685
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) coated mini implant
Trial: 23236685
Drug: Plain mini
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain mini implant (control)
Trial: 10206085
Drug: rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 2 mg in the fasting state
Trial: 10206085
Drug: rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 2 mg following a standard high-fat breakfast
Trial: 157810
Drug: Intravenous tolbutamide
RxNorm normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tolbutamide
Trial: 157810
Drug: Intravenous glibornuride
RxNorm normalized name: glibornuride
DrugBank: Glibornuride (DB08962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glibornuride
Trial: 19671016
Drug: Antibiotic resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic resistance
Trial: 31977129
Drug: Antibiotic-resistant genes
RxNorm normalized name: Genesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-resistant genes
Trial: 31251102
Drug: Honokiol liposome
RxNorm normalized name: honokiol
DrugBank: Honokiol (DB19283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honokiol liposome injection (HKLI)
Trial: 25590308
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline spray
Trial: 18178988
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks
Trial: 15349784
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (12 g l(‐1) solution, 4 aliquots of 250 ml at 30 min intervals before exercise, additional 150 ml every 15 min during exercise)
Trial: 9310273
Drug: Spirapril, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril, 6 mg once daily
Trial: 9310273
Drug: Enalapril, 5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 5-20 mg once daily
Trial: 8339560
Drug: Cyclosporine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 1% ophthalmic ointment
Trial: 3554278
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of compression and O-(beta-hydroxyethyl)-rutosides
Trial: 30830164
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical parameters + biomarkers (leptin + high molecular weight adiponectin + VEGF)
Trial: 26780387
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lenalidomide (15 mg/kg), docetaxel (75 mg/m²), and prednisone (10 mg daily)
Trial: 21146655
Drug: 30 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Trial: 21146655
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Trial: 21146655
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin after 12 months of open-label thienopyridine treatment
Trial: 11976834
Drug: 5-FU with
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU with food (20 mg/m(2), orally)
Trial: 11976834
Drug: 5-FU in
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU in fasted state (20 mg/m(2), orally)
Trial: 2101962
Drug: Clenbuterol (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenbuterol (0.04 mg, p.o.)
Trial: 2101962
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) (50 mg, i.v.) alone
Trial: 2101962
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) (50 mg, i.v.) with Clenbuterol (0.04 mg, p.o.)
Trial: 26483291
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (3 months, 12 weekly sessions)
Trial: 23233719
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg daily + Temsirolimus 30 mg daily (5 days every 2 weeks)
Trial: 9663726
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. after meals for 2 weeks (group LA)
Trial: 9663726
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. + Ecabet sodium 1000 mg b.d. after meals for 2 weeks (group LAE)
Trial: 2932137
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms of nebulized ipratropium bromide after 10 mg salbutamol by nebulizer
Trial: 2932137
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg salbutamol (two doses 2 hours apart)
Trial: 30891604
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of EV71 vaccine (dose 1) and HepB on day 1 and EV71 vaccine (dose 2) and MenA on day 30 (SI group)
Trial: 30891604
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of doses 1 and 2 of EV71 vaccine on days 1 and 30, respectively (SE1 group)
Trial: 30891604
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of HepB and MenA on days 1 and 30, respectively (SE2 group)
Trial: 26891753
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human G-CSF
Trial: 25314773
Drug: 2 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of cytarabine (average dose) in Group 2
Trial: 25314773
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses (100 mg/m2) in combination with idarubicin (8‐12 mg/m2) and mitoxantrone (10 mg/m2) in Group 1
Trial: 22377484
Drug: Strict glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glucose control based on insulin (I-group; n=21)
Trial: 22377484
Drug: Strict glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glucose control based on oral agents (O-group; n=18)
Trial: 17209215
Drug: Multivitamin-multimineral supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin-multimineral supplement with vitamin C, vitamin E, beta-carotene, and zinc (with cupric oxide)
Trial: 17209215
Drug: Additional nutrients
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional nutrients as dietary supplements
Trial: 11134690
Drug: 400-mg caplets
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400-mg caplets of Garcinia cambogia (total dose of 2.4 g/day, 1.2 g/day HCA)
Trial: 30630862
Drug: Azacitidine maintenance
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine maintenance (50 mg/m2, subcutaneously, days 1‐5, every 4 weeks) until relapse, for a maximum of 12 cycles (N = 56)
Trial: 28829514
Drug: Somatostatin retained
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin retained enema, conducted twice every day for at least 30 minutes each time, with treatment courses lasting 7 days.
Trial: 28829514
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment plan (Control group).